Sellas Life Sciences

SELLAS Life Sciences Group Signs Exclusive License Agreement for Global Rights on Development and Commercialization of WT1 Cancer Vaccine with Memorial Sloan Kettering Cancer Center
SELLAS Life Sciences Group To Present at the Annual AEGIS Healthcare & Technology Conference

About Σellas

Sellas Life Sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. In other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide.

Our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of Sellas. We strive to improve patients' quality of life through developing and commercializing cutting-edge innovative therapies.

Sellas is a Swiss based, development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various indications in cancer and the Central Nervous System (CNS). Sellas focuses on in-licensing drug candidates that are undergoing or have already completed initial (pre-) clinical testing and then seeks to further develop those drug candidates for commercial use.